Sclerosis

Wistar Research Identifies Mechanisms for Selective Multiple Sclerosis Treatment Strategy

Retrieved on: 
火曜日, 5月 28, 2024
Wistar, EBV, PML, Bangladesh Technical Education Board, Phenotype, Nature Microbiology, Nervous system, Patient, Data collection, Wistar Institute, TAF, Sclerosis, Immune system, Travel, FOXP1, Disease, DSM-IV codes, Multiple sclerosis, Epstein–Barr virus infection, SLCL, Liebermann, Neuron, Collaborative writing, Gene, Immortalised cell line, Cell, Manuscript, IL-6, Brain, Inflammation, R01, Vaccine

Though researchers know that EBV can contribute to the development of MS, the exact mechanisms by which it does so aren’t completely understood.

Key Points: 
  • Though researchers know that EBV can contribute to the development of MS, the exact mechanisms by which it does so aren’t completely understood.
  • As a whole, the group’s findings suggested a mechanism of lytic EBV in MS that promoted inflammation and disease.
  • TAF also significantly reduced the expression of inflammatory cytokines like IL-6 in the SLCLs from the patients with active MS.
  • The funders had no role in study design; data collection and analysis; decision to publish; or preparation of the manuscript.

Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab

Retrieved on: 
木曜日, 5月 9, 2024
Type 1 diabetes, Lupus, Jefferies Group, Acquisition, Sclerosis, Multiple sclerosis, BLA, Immune system, Music

ImmuNext, a privately-held biotechnology company, is entitled to a royalty on net sales of frexalimab and milestones related to the achievement of regulatory and clinical events and commercial sales.

Key Points: 
  • ImmuNext, a privately-held biotechnology company, is entitled to a royalty on net sales of frexalimab and milestones related to the achievement of regulatory and clinical events and commercial sales.
  • Frexalimab is in three Phase 3 clinical studies for the treatment of multiple sclerosis (MS).
  • Sanofi stated that potential non-risk-adjusted peak sales for frexalimab may be greater than €5 billion (December 7, 2023 R&D Day).
  • Royalty Pharma estimates frexalimab, if approved, will generate royalties through 2041.

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs

Retrieved on: 
火曜日, 5月 7, 2024
Microsoft Exchange Server, Cell, MSC, Research, PBMC, Gene, Applied mathematics, Society, IPSC, ERNA, Inflammation, Stem cell, Sclerosis, IDO1, Cell therapy, Silk

While mesenchymal stem cells (MSCs) have repeatedly demonstrated significant therapeutic potential in numerous preclinical models, their clinical translation has been greatly impeded by variability in therapeutic responses.

Key Points: 
  • While mesenchymal stem cells (MSCs) have repeatedly demonstrated significant therapeutic potential in numerous preclinical models, their clinical translation has been greatly impeded by variability in therapeutic responses.
  • This variability is often attributed to donor and source heterogeneity and limited expansion potential.
  • Furthermore, MSCs can exhibit limited in vivo persistence due to clearance by host immune cells, which can also contribute to deficient therapeutic responses.
  • Induced pluripotent stem cell (iPSC)-derived MSCs (iMSCs) promise to directly address many of the fundamental challenges facing MSC translation.

Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs

Retrieved on: 
火曜日, 5月 7, 2024
Inflammation, NEA, Science, CD19, Patient, Pivotal, Coombs test, B cell, Wellington Management Company, Health, Norwest Venture Partners, I&I, Sclerosis, Multiple sclerosis, Pharmaceutical industry

WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology-directed therapies, today announced the closing of an upsized $200 million Series C preferred stock financing. The financing round was led by SR One along with NEA, Norwest Venture Partners, and Delos Capital with significant participation from Enavate Sciences and Longitude Capital. Additional new investors, the Federated Hermes Kaufmann Funds, and Arrowmark Partners, along with existing investors, Fairmount, Wellington Management, Rock Springs Capital, Pivotal bioVenture Partners, Vivo Capital, Quan Venture Fund, and Superstring Capital participated in the financing. In conjunction with the financing, Jake Nunn, venture partner at SR One, and Tim Xiao, Partner at Delos Capital, joined Zenas’ Board of Directors.

Key Points: 
  • The financing round was led by SR One along with NEA, Norwest Venture Partners, and Delos Capital with significant participation from Enavate Sciences and Longitude Capital.
  • In conjunction with the financing, Jake Nunn, venture partner at SR One, and Tim Xiao, Partner at Delos Capital, joined Zenas’ Board of Directors.
  • “Their commitment to Zenas is a testament to our vision to be a global leader in bringing innovative immunology-based therapies to patients around the world.
  • “At SR One, we invest in companies like Zenas whose science has the potential to rewrite the medical textbooks and meaningfully transform patient care.

TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

Retrieved on: 
木曜日, 4月 18, 2024
American Academy, University, Participation, MD, Research, Publication, Patient, RMS, AAN, USF, Sclerosis, Multiple sclerosis, Poster, Therapy, Pharmaceutical industry

NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two additional data presentations from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 American Academy of Neurology (AAN) annual meeting, being held in Denver, Colorado.

Key Points: 
  • NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two additional data presentations from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 American Academy of Neurology (AAN) annual meeting, being held in Denver, Colorado.
  • Links to the data presented yesterday are included below.
  • Michael S. Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated “The data presented this week during the AAN annual meeting emphasizes our commitment to research and the multiple sclerosis community.
  • We look forward to continuing to evaluate date from the ULTIMATE Phase 3 trials and presenting additional exploratory data throughout the year.”
    Link to Poster Presentation: Ublituximab Significantly Reduces Radiological Disease Activity at 12 Weeks: Post-hoc analysis of Participants with Highly Active Disease in the ULTIMATE I & II Phase 3 Studies
    Lead Author: Derrick Robertson, MD - University of South Florida (USF) Morsani College of Medicine in Tampa, Florida
    Lead Author: Derrick Robertson, MD - University of South Florida (USF) Morsani College of Medicine in Tampa, Florida
    All data presented at AAN is also available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm .

BJ's RESTAURANT & BREWHOUSE® HONORED AS BEST MULTI-UNIT CHAIN RESTAURANT GROUP BY THE 2024 QUESTEX VIBE VISTA AWARDS

Retrieved on: 
木曜日, 4月 18, 2024
Restaurant, Drink, Conference, Research, Peach, Johnson & Wales University, Sclerosis, Caramel Apple Pops, Grand Marnier, BJ's Restaurants, Hotel

HUNTINGTON BEACH, Calif., April 18, 2024 /PRNewswire/ -- BJ's Restaurant & Brewhouse® (NASDAQ: BJRI) is feeling the good vibrations after receiving the Vibe Vista Award for Best Multi-Chain Restaurant Group at Questex's 2024 Vibe Conference, the premier conference for on-premise beverage industry executives. Recognizing the top performers in the beverage industry, the Vibe Vista Awards honored BJ's achievements in the creation, execution, management and ongoing positive results of its beverage program, which was enhanced and augmented in 2023.

Key Points: 
  • HUNTINGTON BEACH, Calif., April 18, 2024 /PRNewswire/ -- BJ's Restaurant & Brewhouse® (NASDAQ: BJRI) is feeling the good vibrations after receiving the Vibe Vista Award for Best Multi-Chain Restaurant Group at Questex's 2024 Vibe Conference, the premier conference for on-premise beverage industry executives.
  • The 2024 Vibe Vista Award win reflects the significant enhancements and new offerings BJ's added to its overall beverage program.
  • Tim McLucas, Questex Vice President, Bar & Restaurant, said, "Congratulations to the 2024 Vibe Vista Awards winners.
  • Vibe Vista Awards entries were judged by a panel of Johnson & Wales University beverage faculty staff and alumni, together with Technomic and SevenFifty Daily and Beverage Media Group.

EQS-News: Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States

Retrieved on: 
水曜日, 4月 10, 2024
Biotechnology, Patent, Multiple sclerosis, Calcium, Into, Sclerosis, Pharmaceutical industry

The patent was previously granted to the company in Australia, Canada, Indonesia, Japan and Mexico.

Key Points: 
  • The patent was previously granted to the company in Australia, Canada, Indonesia, Japan and Mexico.
  • “Allowance of this key composition-of-matter patent, covering the specific polymorph of vidofludimus calcium, provides another important layer of proprietary intellectual property protection around our lead, late-stage asset,” stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.
  • “A significant part of this patent will also cover the related method of producing material of vidofludimus calcium used in our studies.
  • On top of the patent exclusivity, vidofludimus calcium, as a new chemical entity, should also benefit from regulatory data protection.

Merz Enters Asset Purchase Agreement With a US-Based Biotech Company

Retrieved on: 
火曜日, 4月 2, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Finance, Health, Professional Services, Growth, PD, Patient, Merz, Sale, Acquisition, Sclerosis, Parkinson's disease, DSM-IV codes, Therapy, Acorda Therapeutics, Physician, Pharmaceutical industry

Merz Therapeutics, a business of Frankfurt-based Merz Group, has entered into an Asset Purchase Agreement to acquire two commercial medicines from NASDAQ-listed Acorda Therapeutics.

Key Points: 
  • Merz Therapeutics, a business of Frankfurt-based Merz Group, has entered into an Asset Purchase Agreement to acquire two commercial medicines from NASDAQ-listed Acorda Therapeutics.
  • Closing of the transaction would significantly contribute to the accelerated growth strategy of Merz Therapeutics.
  • This investment would add significantly to Merz Therapeutics growth strategy and expand our portfolio in the field of movement disorders and neurodegeneration.
  • As a German-based but global company, we are very interested in innovative acquisitions, on a global scale," concludes Jörg Bergler.

The Multiple Sclerosis Association of America (MSAA) Selects SEQSTER to Accelerate Patient-Centricity & Innovation

Retrieved on: 
土曜日, 3月 23, 2024
Science, Neurology, Software, Research, Health, Data Management, Health Technology, Technology, MSIN, Acceleration, Learning, Multiple sclerosis, 1-Click, Dell Medical School, Sclerosis, MSAA, Doctor of Philosophy, MD, University, Implementation Science, Novartis, Population health, Multimedia, Medical director, Nursing

SEQSTER PDM Inc. (“ SEQSTER ”), the leading patient-centric healthcare technology company, has been selected by the Multiple Sclerosis Association of America (MSAA) for its patient-centricity, 1-Click Records™ and cutting-edge longitudinal health record.

Key Points: 
  • SEQSTER PDM Inc. (“ SEQSTER ”), the leading patient-centric healthcare technology company, has been selected by the Multiple Sclerosis Association of America (MSAA) for its patient-centricity, 1-Click Records™ and cutting-edge longitudinal health record.
  • SEQSTER unifies people living with multiple sclerosis (MS), researchers, and care centers nationwide.
  • View the full release here: https://www.businesswire.com/news/home/20240321509514/en/
    Multiple Sclerosis Association of America (MSAA) Selects SEQSTER to Accelerate Patient-Centricity & Innovation (Graphic: Business Wire)
    This announcement follows the creation of the Multiple Sclerosis Implementation Network™ (MSIN™), which MSAA launched in collaboration with Novartis Pharmaceuticals Corporation in May 2023.
  • "I am deeply honored and profoundly excited to witness the remarkable collaboration between MSAA, clinicians, academic researchers, industry partners, and SEQSTER for the Multiple Sclerosis Implementation Network.

Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States

Retrieved on: 
水曜日, 3月 20, 2024
Biotechnology, Patent, Multiple sclerosis, Calcium, Into, Sclerosis, Pharmaceutical industry

NEW YORK, March 20, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application 16/981,122, entitled, "Calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferative agents," covering the composition-of-matter of a specific polymorph of vidofludimus calcium (IMU-838) and a related method of production of the material. The claims are expected to provide protection into 2039, unless extended further. The patent was previously granted to the company in Australia, Canada, Indonesia, Japan and Mexico.

Key Points: 
  • "Allowance of this key composition-of-matter patent, covering the specific polymorph of vidofludimus calcium, provides another important layer of proprietary intellectual property protection around our lead, late-stage asset," stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.
  • "A significant part of this patent will also cover the related method of producing material of vidofludimus calcium used in our studies.
  • Vidofludimus calcium is covered by several layers of granted patents in the United States, Europe and other jurisdictions around the world.
  • On top of the patent exclusivity, vidofludimus calcium, as a new chemical entity, should also benefit from regulatory data protection.